Immune cell therapy shows promise for tough myasthenia gravis cases

NCT ID NCT06371040

Recruiting now Disease control Sponsor: Ting Chang, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new type of immune cell therapy called CD19-BCMA CAR-T in 9 adults with severe myasthenia gravis that hasn't improved with standard treatments. The therapy uses a patient's own modified immune cells to target and attack the faulty cells causing the disease. The main goal is to check safety and find the right dose, while also looking for signs of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-BCMA CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with severe myasthenia gravis that doesn't respond to standard therapies.
What could go wrong: This is a very early, small phase 1 trial with only 9 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

Tangdu Hospital, The Fourth Military Medical University
RECRUITING

Xi'an, Shaanxi, 710038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.